Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Zweegman, Sonja, Stege, Claudia A.M., Haukas, Einar, Schjesvold, Fredrik H., Levin, Mark-David, Waage, Anders, Leys, Rineke B.L., Klein, Saskia K., Szatkowski, Damian, Axelsson, Per, Hieu Do, Trung, KJournal:
Haematologica
DOI:
10.3324/haematol.2019.240374
Date:
February, 2020
File:
PDF, 1.02 MB
2020
File converter
More search results
More benefits 
